What Is Romiplostim? Definition and What Research Reports
Romiplostim is an engineered protein that activates the thrombopoietin receptor on megakaryocytes and their precursors. Structurally it is a "peptibody" — a synthetic peptide domain fused to an antibody Fc fragment — so it sits between peptide pharmacology and biologic protein drugs. Published work has examined it mainly in immune thrombocytopenia, chemotherapy-induced thrombocytopenia, refractory aplastic anaemia and stem-cell transplant settings, plus laboratory comparisons with thrombopoietin and eltrombopag. This entry is definitional and summarises the literature only.
Definition
Romiplostim is a laboratory-engineered protein that stimulates the thrombopoietin receptor (TPO-R, also written MPL or c-Mpl) found on megakaryocytes and their bone-marrow precursors; a 2021 review characterised its mechanism of action as agonism at that receptor, driving megakaryocyte maturation and platelet production, and surveyed where that mechanism has been applied clinically (PMID 34079225). It is an approved prescription biologic that is administered by or under the direction of clinicians, not a research-only compound. In peptide-focused reading, the name appears most often as a worked example of how a designed peptide sequence — one that shares no sequence identity with the natural hormone it imitates — can be engineered into a long-circulating therapeutic.
What Class of Molecule Is Romiplostim?
Romiplostim is usually described as a peptibody: a synthetic peptide domain covalently linked to an immunoglobulin Fc fragment. The peptide portion supplies receptor binding, while the Fc portion supplies the extended circulating half-life that a bare short peptide would not have. The 2021 mechanism review set out this design and explained that romiplostim engages the thrombopoietin receptor without sharing amino-acid sequence homology with endogenous thrombopoietin (PMID 34079225). The molecule is produced by recombinant expression rather than by chemical synthesis of a single linear chain, which is one reason it is classified as a biologic rather than as a conventional small peptide.
How the Term Is Used in Peptide Research
Three usages recur in the literature:
- As a mechanism label. Papers use "romiplostim" as shorthand for TPO-receptor agonism delivered by a peptide-Fc construct, in contrast with small-molecule agonists such as eltrombopag and with recombinant thrombopoietin itself; researchers directly compared the expansion effect of romiplostim on haematopoietic stem and progenitor cells against thrombopoietin and eltrombopag in a 2024 laboratory study (PMID 39302624).
- As a design case study. The peptibody format is cited when authors discuss how peptide agonists can be given antibody-like pharmacokinetics, a point covered in the 2021 mechanism review (PMID 34079225).
- As a clinical comparator. Disease-focused reviews use romiplostim as the reference agent when describing platelet-directed therapy — for example a 2024 review of immune thrombocytopenia pathophysiology that also examined the impacts of romiplostim treatment (PMID 38942688).
What the Published Literature Reports
Immune thrombocytopenia (ITP)
ITP is the setting in which romiplostim is most established. A 2024 review in Blood Reviews described the pathophysiology of immune thrombocytopenia and discussed the impacts of romiplostim treatment within that disease framework (PMID 38942688). The 2021 mechanism review placed ITP among the principal areas of clinical applicability for TPO-receptor agonism (PMID 34079225).
Chemotherapy-induced thrombocytopenia (CIT)
A 2019 report in the Journal of Clinical Oncology examined romiplostim treatment of chemotherapy-induced thrombocytopenia (PMID 31545663). A randomised comparison of romiplostim versus placebo for chemotherapy-induced thrombocytopenia was subsequently published in the New England Journal of Medicine (PMID 41812193). A 2024 review in Cancer Medicine synthesised the CIT literature on romiplostim (PMID 39135303), and a separate 2024 report described its use for antineoplastic therapy-induced thrombocytopenia in gynaecologic and breast cancers (PMID 38757118).
Aplastic anaemia and marrow failure
A Phase II/III, multicentre, open-label study reported on the efficacy and safety of romiplostim in refractory aplastic anaemia (PMID 33152120). Building on that work, a 2025 analysis pooled data from two clinical trials to identify predictive factors of romiplostim response in patients with refractory aplastic anaemia (PMID 40593138). A further 2025 report described high-dose romiplostim in the setting of donor-type aplasia (PMID 40504447). None of these publications establishes romiplostim as a general-purpose treatment; each describes a specific, closely monitored haematology population.
Transplantation and paediatrics
A 2025 paper in Pediatric Transplantation assessed the utility and safety of romiplostim in paediatric allogeneic stem cell transplantation (PMID 41254453). The laboratory comparison of romiplostim, thrombopoietin and eltrombopag on haematopoietic stem and progenitor cell expansion is relevant to this line of work, since it examined the agents' effects on progenitor populations rather than on platelets alone (PMID 39302624).
Veterinary literature
Outside human medicine, a 2024 retrospective assessment in the Journal of Veterinary Internal Medicine described romiplostim use for thrombocytopenia in dogs and reported clinical outcomes in that cohort (PMID 39023218). Veterinary findings are reported here only to show the breadth of the published record; they are not extrapolated to people.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhere Romiplostim Has Been Studied: Quick Reference
| Research area | Example publication | What it examined |
|---|---|---|
| Mechanism and drug class | PMID 34079225 | TPO-receptor agonism and clinical applicability, as reviewed in 2021 |
| Immune thrombocytopenia | PMID 38942688 | Disease pathophysiology and impacts of romiplostim treatment |
| Chemotherapy-induced thrombocytopenia | PMID 41812193 | Romiplostim compared with placebo |
| Refractory aplastic anaemia | PMID 33152120 | Efficacy and safety in a Phase II/III open-label study |
| Stem and progenitor cell biology | PMID 39302624 | Expansion effect versus thrombopoietin and eltrombopag |
| Veterinary use | PMID 39023218 | Retrospective outcomes in dogs with thrombocytopenia |
Safety and Tolerability: What Studies Report
Safety has generally been reported alongside efficacy rather than in isolation. The Phase II/III open-label study in refractory aplastic anaemia was designed to report both efficacy and safety outcomes (PMID 33152120), and the paediatric allogeneic stem cell transplantation paper likewise assessed utility together with safety (PMID 41254453). The randomised placebo-controlled comparison in chemotherapy-induced thrombocytopenia provides the controlled context in which adverse events can be interpreted (PMID 41812193), while the 2024 Cancer Medicine review collated safety observations across the CIT literature (PMID 39135303). Because romiplostim acts on marrow progenitors, monitoring in these studies extended beyond platelet counts alone, a point reflected in laboratory work on progenitor expansion (PMID 39302624).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appTerms Often Confused With Romiplostim
- Thrombopoietin (TPO): the endogenous hormone. Romiplostim mimics its receptor activity without sharing its sequence, as described in the 2021 mechanism review (PMID 34079225).
- Eltrombopag: a separate, orally administered TPO-receptor agonist; researchers compared it head-to-head with romiplostim and thrombopoietin for progenitor expansion in a 2024 study (PMID 39302624).
- Peptibody versus peptide: romiplostim's Fc fusion means it behaves pharmacokinetically more like an antibody-derived biologic than like a short unmodified peptide (PMID 34079225).
Scope of This Entry
This glossary entry defines the term and summarises what published studies examined; it does not describe schedules, quantities, titration or monitoring, and it draws no conclusions about individual suitability. Romiplostim is a regulated prescription biologic, and the studies cited were conducted in supervised clinical or laboratory settings with defined patient populations. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or laboratory finding.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- A Review of Romiplostim Mechanism of Action and Clinical Applicability (Drug Design, Development and Therapy, 2021)
- Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment (Blood Reviews, 2024)
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia (Journal of Clinical Oncology, 2019)
- Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia (The New England Journal of Medicine, 2026)
- Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature (Cancer Medicine, 2024)
- Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers (Gynecologic Oncology Reports, 2024)
- Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study (British Journal of Haematology, 2021)
- Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials (Annals of Hematology, 2025)
- High-dose romiplostim for donor-type aplasia (Annals of Hematology, 2025)
- Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation (Pediatric Transplantation, 2025)
- Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag (International Journal of Hematology, 2024)
- Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes (Journal of Veterinary Internal Medicine, 2024)
Frequently asked questions
Is romiplostim a peptide or a biologic?▾
Both descriptions appear in the literature. Romiplostim is a peptibody: a synthetic peptide domain fused to an immunoglobulin Fc fragment, which gives it antibody-like pharmacokinetics. A 2021 review described this design and explained that the molecule engages the thrombopoietin receptor without sharing sequence homology with the natural hormone (PMID 34079225). It is regulated as a prescription biologic, not as a research chemical.
What does romiplostim do at the cellular level?▾
It acts as an agonist at the thrombopoietin receptor (TPO-R/MPL) on megakaryocytes and their precursors, which is the same receptor the endogenous hormone uses. A 2021 review summarised this mechanism and its clinical applicability (PMID 34079225). A separate 2024 laboratory study compared romiplostim's expansion effect on haematopoietic stem and progenitor cells with thrombopoietin and eltrombopag (PMID 39302624).
Which conditions has romiplostim been studied in?▾
Published work centres on immune thrombocytopenia, where a 2024 review examined disease pathophysiology and the impacts of romiplostim treatment (PMID 38942688); chemotherapy-induced thrombocytopenia, including a placebo-controlled comparison (PMID 41812193); and refractory aplastic anaemia, examined in a Phase II/III open-label study (PMID 33152120). Reports also exist in paediatric allogeneic stem cell transplantation (PMID 41254453).
How does romiplostim differ from eltrombopag?▾
Both act at the thrombopoietin receptor, but they are different molecule classes: romiplostim is a peptide-Fc fusion protein, while eltrombopag is a small molecule taken orally. Researchers compared romiplostim, thrombopoietin and eltrombopag directly for their expansion effect on haematopoietic stem and progenitor cells in a 2024 study (PMID 39302624). Clinical differences are discussed in the disease-specific literature rather than assumed.
What do studies report about romiplostim safety?▾
Safety has typically been reported alongside efficacy. A Phase II/III, multicentre, open-label study evaluated efficacy and safety in refractory aplastic anaemia (PMID 33152120), and a 2025 paper assessed utility and safety in paediatric allogeneic stem cell transplantation (PMID 41254453). A 2024 review collated safety observations across the chemotherapy-induced thrombocytopenia literature (PMID 39135303). This is educational summary only, not medical advice.
Has romiplostim been studied in animals?▾
Yes. A 2024 retrospective assessment in the Journal of Veterinary Internal Medicine described romiplostim use for thrombocytopenia in dogs and reported clinical outcomes in that cohort (PMID 39023218). Veterinary data are reported in the literature as a distinct body of evidence and are not treated by researchers as interchangeable with human findings.
Why does romiplostim appear in peptide glossaries?▾
Because it is a widely cited example of peptide engineering: a designed peptide sequence that mimics a hormone it does not resemble, stabilised by fusion to an Fc fragment. The 2021 mechanism review set out that structure-function relationship (PMID 34079225). The term is used definitionally in peptide reference material, not as an indication that the agent is available outside clinical settings.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.